`(PATENT)
`
`IN THE UNlTE:O STATES PATENT AND TRADEMARK Ol''FlCE
`
`In re application of: G ALLAGI-fER, Cynthia, et al. Examiner: MIKNIS, Zachary l
`Application No.:. 14/855,168
`Group Ait Unit: 8760
`Confirmation No.: 1675
`Filed: September 15,2015
`For: Cl-INH COMPOSITIONS AND METHODS FOR THE PREVENTION AND
`TREATMENT OF DISORDERS ASSOCIATED \VITH CJ ESTERASE INHIBITOR
`DEFICI:ENCY
`
`VIA EJ<'S WRB FILING- WWW.USJ>TO.GOV
`
`Commissioner for Patents
`P.O. Box 1450
`Alexandria, VA22313-1450
`
`DECLARATION OF DR. 1\f{<=;.HAIU. M. :FRANK UNnER 37 C . .F.R. § 1.132
`
`Dear Commissioner:
`
`I, Michael M. Frank, hereby declare as follows:
`
`1 .
`
`1 am a co-author in the paper Jiang et al., "Subcutaneous infusion ofhtunan C 1
`
`inhibitor .in swine,'' Clinical Imrmm.ology 136:323- 328, published 8 June 20 l 0 ("Jiang")
`
`(hereinafter referred to as "Jiang").
`
`2.
`
`The studies described in this paper were dt:signed and conducled intny laboratory
`
`to compare plasma levels, assess the ti.me t.o peak levels and duration of mainterumce, and to
`
`assess the safety ofh\nrwn Cl inhibitoradm:iniste.red subcutaneously ve.rsLls intravenously. Jiang
`
`atp .. 324.
`
`3.
`
`CINRYZE',j) (ViroPbanna, Inc.), a purified preparation of human plasma-derived
`
`C 1 inhibitor was t)sed as the source of Cl inhibitor used in these studies.
`
`CSL EXHIBIT 1003
`CSL v. Shire
`
`Page 1 of 2
`
`
`
`Galiagher, eta!.
`In re
`AppL No.; 14i855, 168
`Filed
`September 15,2015
`Page
`2 of2
`
`Attorney's Docket No.: 2006685-1184
`
`4.
`
`CINRYZE'iP \vas prepared according to the instructions provided in the
`
`prescribing information. Accordingly, each 500 Uvial was reconstit1..1ted v,.'ith 5 1nL of ste1ile
`
`vvater to achieve a En a! C l-INH concentration of 100 U/mL The same I 00 U/mL preparation
`
`was administered to each animal, with some receiving the drug subcutaneously and some
`
`intravenouslv.
`"
`
`5.
`
`The pigs were dosed at 50 U/kg. As the pigs ranged in \\'eight from 16-23 kg, the
`
`total dose administered ranged from 800 U to 1150 U of C 1-INH. Accordingly, the volume of
`
`1 00 U/mL preparation adtninistered ranged from 8 mL to 11.5 mL.
`
`6.
`
`The intravt~nous administration of the 100 U/mL preparation was perfl1nned over
`
`a 30 minute injection time in order to simulate intravenous administration in humans.
`
`7.
`
`The subcutaneous administration of the 100 U/rnL preparation w·as performed b)''
`
`subcutaneous infusion delivered by continuous pump over a 60--minute per1od. This vms
`
`necessary due to the large volume of preparation administered to the pigs.
`
`8. All statements made herein of my own knowledge are true and all statements made on
`
`information and belief are believed to be true; and further these statements were nmde with the
`
`knowledge that \Viliful false statements and the like so made are punishable by fine or
`
`imprisonment or both, under Section 1001 of Title 18 of the United States Code and that such
`
`willful false statements may jeopardize the validity of the present application or any patent
`
`issued in reliance thereon.
`
`Date:
`
`Page 2 of 2
`
`